Alnylam to Webcast R&D Day
Alnylam management and leading physicians will discuss development candidates from the company's RNAi therapeutics pipeline. The event will include presentations from the following guest speakers:
Ole Suhr, M.D., Ph.D.
Chief Physician and Gastroenterologist at the
Department of Medicine, and Head of the Amyloid team at the Umeå University Hospital
Robert Desnick, M.D., Ph.D.
Dean for Genetic & Genomic Medicine, Professor and Chair Emeritus at the
Icahn School of Medicine at Mount Sinai
John Pasi, MB, ChB, Ph.D., FRCP, FRCPath, FRCPCH
Professor of Haemostasis and Thrombosis and Consultant Haematologist at Barts and the
London School of Medicine and Dentistry, Queen Mary, University of London
The meeting will be held on
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across its 3 STArs. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including
Investors and Media
News Provided by Acquire Media